Výsledky vyhledávání

Clinical Activity of Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring Ros1 Gene Rearrangement

Autor: M. Dietel, M. von Laffert, A. Lavole, S.I. Ou, D. Li, P. Lohneis, A. Van Baardwijk, Jeffrey W. Clark, Yuankai Shi, S. Temraz, Marileila Varella-Garcia, N.S. Turhal, L. Zhao, J.X. Zhou, Laurent Greillier, Faysal Dane, Savas Topuk, Tony Mok, H. Pang, Julia Bonastre, N. Yamamoto, Stephen L. Graziano, M. Wolf, K. Fujimoto-Ouchi, Martin H. Falk, S. Niho, M. Han, A. Grigorescu, R. Lamy, Victoria Soldatenkova, Miyako Satouchi, Dirk De Ruysscher, D.R. Camidge, M. Oellers, Rinus Wanders, G. Nalbantov, Pierre Hainaut, Paul Baas, H. Kreipe, W. El-Sadda, S. Kudoh, X.L. Firvida, M. Lazaro, Yang Sun, Miklos Pless, D. Lenze, Perran Fulden Yumuk, Katsuyuki Hotta, Carla Visseren-Grul, K. Tsujino, T. Tamura, L. Tye, Yoshihiro Nishimura, W. Slichenmyer, K. Kubota, Vanessa Rousseau, Jeffrey A. Engelman, T. Orlowski, D. Smith, R.N. Murray, Yang Yao, X. Hu, X. Wang, R. Vandendries, M. El-Ashry, R. Varea, N. Kuriyama, J. Kiemle-Kallee, P. He, C. Le Pechoux, Philippe Lambin, I.A. Koroleva, Bart Reymen, A. Vergnenegre, A. Reuss, J.E. Castro, Hirohisa Yoshizawa, W-T. Lim, R. Penzel, J.P. Pignon, H.H. Strøm, G. Karaüç, Kevin Jasas, J.G. Kutyreva, M.V. Kopp, Y. Liu, N. Chouaki, J.R. Fischer, C. Chouaid, M. Das, Ariane Dunant, E. Hernández, W. Jochum, P. Schnabel, S.E. Boeru, Cem Parlak, T. Korse, K. McKee, Kazuhiko Nakagawa, W. Van Elmpt, Lesley Seymour, Yasutaka Chiba, A.D. Vincent, M. Perol, Kwan Park, A. He, I. Borget, L.V. Shaplygin, I. Petersen, Janneke P.C. Grutters, K. Wilner, X. Ma, R. von Moos, J. Casal Rubio, K. Furugaki, H. Sharifi, P. Gopalakrishna, R. Sekiguchi, G. Zalcman, Z. Akgün Cetinkaya, S. Atagi, V. Lee, W. Dyszkiewicz, J. Belderbos, S. Agarwal, Colum Smith, M. Credi, T. Iwai, R. Ramlau, B.L.T. Ramaekers, G. Bootsma, Shaoming Wang, Wei-Xiang Qi, A. Spira, Béranger Lueza, J. Jiang, P. Schirmacher, Ozgur Ozyilkan, M. van den Heuvel, N. Helbekkmo, D. Betticher, Y. Moriya, I. Abdel Halim, X. Han, Jianxing He, I. Turtoi, X. Gu, M. Meister, F. Barón, M. Chabowski, B. Taboada, T. Akimoto, Michael Thomas, N. Nogami, Martin Filipits, W. Uyterlinde, N. Pourel, Yasuhito Fujisaka, Benjamin Lacas, E.H. Tan, I. Martel-Lafay, Michael Hummel, Toyoaki Hida, S. Barriga, Katsuyuki Kiura, U. Aasebø, Lin Gui, Anthony J. Iafrate, Andrew Maksymiuk, S. Sundstrøm, I. Sekine, Denis Soulières, Y. Ohe, Sotaro Enatsu, M. Zhao, H. Yang, H. Nokihara, S. Chabaud, Sarayut Lucien Geater, R. Bremnes, M. Vieito Villar, M.A. Joore, Charles Butts, C. Pena, R. Gervais, D. Perol, N. Sunnetci, K. Nihei, A.H. Loos, Niels Reinmuth, Glenwood D. Goss, M. Öllers, M. Salzberg, Stefan Scherer, A-M.C. Dingemans, E. Berg, N.N. Zhang, C. Droege, Erkan Topkan, Q. Deng, Alice T. Shaw, Sumitra Thongprasert, Reinhard Büttner, J. Li, C. Reynolds, J. Sonke, P. Fournel, Audrey Mauguen, Peter M. Ellis, F. Lin, N. Ianotti, S. Vazquez, S.V. Kozlov, M.E. Popova, L. Ma, I. Alsan Cetin, L. Zheng, M. Tsao, Jean-Yves Douillard, Y. Ito, P. Stephenson, Zan Shen, D. Arpin, A. Madroszyk, Beste M. Atasoy, M. Sumi

Publikováno v: Annals of Oncology. 23:ix389

Background Chromosomal rearrangements in the receptor tyrosine kinase (RTK) ROS1 define a new molecular subset of NSCLC. ALK inhibitors can inhibit ROS1 kinase activity in cell lines. We examined the efficacy and safety of crizotinib, a small molecul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c852a0e08ddb2ea1c1b82f6da52d9ca7
https://doi.org/10.1093/annonc/mds408

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání